RNA Outsourcing Videos
-
Key Benefits Of PCR-Based mRNA Manufacturing For Clinical Development
6/12/2023
To unlock the potential of your mRNA therapies and accelerate your development and manufacturing program, discover the benefits of a novel PCR-based mRNA drug substance manufacturing process.
-
Who's In Charge? How To Ensure Effective Trial Oversight, Leadership
3/19/2025
Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.
-
Bringing Your mRNA-Based Drug From Pre-Clinical To Commercial
5/24/2024
Watch to explore how you can speed up your mRNA-based drug projects, reduce risks, and shorten time to market with comprehensive and seamless processes from pre-clinical development to commercialization.
-
Intelligent mRNA Manufacturing Through Process Analytical Technologies
3/10/2025
Learn how predictive models can monitor key CQAs, such as RNA concentration and nucleoside triphosphate consumption, and explore RBP and MIT’s vision for revolutionizing biomanufacturing.
-
ICH E6(R3): Practical Steps For Implementation
12/14/2023
Watch this presentation to equip stakeholders with actionable strategies and a comprehensive understanding of the evolving clinical trial management landscape in the context of ICH guidelines.
-
Face- Phase-Off: Matching CDMO Capabilities To Your mRNA-LNP Development Stage
2/10/2025
There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.
-
How "Successful" Are Our mRNA-LNP Outsourcing Partnerships Today?
2/10/2025
In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?
-
How Can Sponsors & CDMOs Collaborate On RNA Analytical/Process Development?
8/22/2024
Having worked on both the innovator and CDMO sides of the industry, Advancing RNA LIVE panelist Khaled Yamout outlines where he sees the greatest weaknesses in these critical sponsor-CDMO partnerships and offers guidance.
-
ReciBioPharm Capacity Update July 2025: Analytical Services
7/28/2025
ReciBioPharm’s specialized CDMO capabilities include development and manufacture for new biological modalities. Discover the benefits of choosing a CDMO with complete end-to-end services and in-house analytical capabilities.
-
How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic
1/31/2023
Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.